BCL9L Polyclonal Antibody, Invitrogen™
Manufacturer: Thermo Scientific
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | PIPA521111-Each-of-1 | In Stock | ₹ 46,057.50 |
PIPA521111 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 46,057.50
GST (18%): ₹ 8,290.35
Total Price: ₹ 54,347.85
Antigen
BCL9L
Classification
Polyclonal
Conjugate
Unconjugated
Gene
BCL9L
Gene Alias
B cell CLL/lymphoma 9-like; B9L; BC003321; B-cell CLL/lymphoma 9-like; B-cell CLL/lymphoma 9-like protein; B-cell lymphoma 9-like protein; BCL9-2; BCL9L; BCL9-like protein; BCL9-related beta-catenin-binding protein; DLNB11; nuclear co-factor of beta-catenin signalling; protein BCL9-2
Host Species
Rabbit
Purification Method
Antigen affinity chromatography
Regulatory Status
RUO
Gene ID (Entrez)
283149
Content And Storage
Maintain refrigerated at 2-8°C for up to 3 months. For long term storage store at -20°C
Form
Liquid
Applications
Immunocytochemistry, Immunohistochemistry, Western Blot
Concentration
1 mg/mL
Formulation
PBS with 0.02% sodium azide
Gene Accession No.
Q86UU0
Gene Symbols
BCL9L
Immunogen
A 20 amino acid peptide near the amino terminus of human Bcl9L.
Quantity
100 μg
Primary or Secondary
Primary
Target Species
Human
Product Type
Antibody
Isotype
IgG
Related Products
Description
- A suggested positive control is Hela cell lysate
- PA5-21111 can be used with blocking peptide PEP-1225
- Bcl9L, a homolog of Bcl9, was initially identified through a bioinformatics screening
- It is expressed in fetal brain, adult lung, eye and prostate, in addition to several types of tumors including pancreatic and prostate cancers
- Bcl9L has been shown to interact with beta-catenin, a target of the Wnt signaling pathway, and is required for enhanced beta-catenin-T-cell factor (TCF)-mediated transcription in colorectal tumor cells, possibly by translocating beta-catenin to the nucleus
- Other studies have indicated that Bcl9L expression correlates with high nuclear grade cancer phenotype and the expression of ErbB2/HER-2 in breast cancers, suggesting that activity may occur in other types of cancer
- Bcl9L has also been shown to be critical for Wnt-mediate regulation of stem cell traits in colon epithelium and adenocarcinomas which are associated with tumor invasion, metastasis, and resistance to therapy.